184 related articles for article (PubMed ID: 26500282)
1. Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
Adam K; Lambert M; Lestang E; Champenois G; Dusanter-Fourt I; Tamburini J; Bouscary D; Lacombe C; Zermati Y; Mayeux P
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26500282
[TBL] [Abstract][Full Text] [Related]
2. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
[TBL] [Abstract][Full Text] [Related]
3. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.
Lu J; Zavorotinskaya T; Dai Y; Niu XH; Castillo J; Sim J; Yu J; Wang Y; Langowski JL; Holash J; Shannon K; Garcia PD
Blood; 2013 Aug; 122(9):1610-20. PubMed ID: 23818547
[TBL] [Abstract][Full Text] [Related]
4. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
5. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
Nair JR; Caserta J; Belko K; Howell T; Fetterly G; Baldino C; Lee KP
Leukemia; 2017 Aug; 31(8):1715-1726. PubMed ID: 28008178
[TBL] [Abstract][Full Text] [Related]
6. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
[TBL] [Abstract][Full Text] [Related]
7. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
8. Pim2 is important for regulating DNA damage response in multiple myeloma cells.
Ramachandran J; Santo L; Siu KT; Panaroni C; Raje N
Blood Cancer J; 2016 Aug; 6(8):e462. PubMed ID: 27564460
[TBL] [Abstract][Full Text] [Related]
9. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
10. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.
Gómez-Abad C; Pisonero H; Blanco-Aparicio C; Roncador G; González-Menchén A; Martinez-Climent JA; Mata E; Rodríguez ME; Muñoz-González G; Sánchez-Beato M; Leal JF; Bischoff JR; Piris MA
Blood; 2011 Nov; 118(20):5517-27. PubMed ID: 21937691
[TBL] [Abstract][Full Text] [Related]
11. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
Haas M; Caron G; Chatonnet F; Manenti S; Alaterre E; Devin J; Delaloy C; Bertolin G; Viel R; Pignarre A; Llamas-Gutierrez F; Marchalot A; Decaux O; Tarte K; Delpy L; Moreaux J; Fest T
Blood; 2022 Apr; 139(15):2316-2337. PubMed ID: 35108359
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
13. PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.
Ren C; Yang T; Qiao P; Wang L; Han X; Lv S; Sun Y; Liu Z; Du Y; Yu Z
Mol Oncol; 2018 May; 12(5):690-704. PubMed ID: 29570932
[TBL] [Abstract][Full Text] [Related]
14. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
15. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
16. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
[TBL] [Abstract][Full Text] [Related]
17. Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J; Hiasa M; Oda A; Harada T; Nakamura S; Amachi R; Tenshin H; Iwasa M; Fujii S; Kagawa K; Miki H; Kurahashi K; Yoshida S; Endo I; Haneji T; Matsumoto T; Abe M
Br J Haematol; 2018 Feb; 180(4):581-585. PubMed ID: 27748523
[No Abstract] [Full Text] [Related]
18. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
[TBL] [Abstract][Full Text] [Related]
19. Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.
Katsuta E; Gil-Moore M; Moore J; Yousif M; Adjei AA; Ding Y; Caserta J; Baldino CM; Lee KP; Gelman IH; Takabe K; Opyrchal M
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 35920189
[TBL] [Abstract][Full Text] [Related]
20. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]